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ABSTRACT 
Polymers  are  used  in  several  immunological  applications,  for  example  in 
designing new generation vaccines, implantation studies, therapeutics and for the 
development  of  animal  models  that  are  mimicking  human  pathological 
conditions.  Polymers  can  function  as  attenuators  to  modulate  host  immune 
responses in tissue transplantation, as suppressors to inhibit immune responses 
against  therapeutics or as an adjuvant in the activation of immune responses. 
Among  them,  polymers  as  adjuvants  are  highly  promising  and  are  being 
developed in the vaccination and autoimmunity fields. As an adjuvant, polymers 
can  efficiently  deliver  antigens  and  have  the  ability  to  modulate  immune 
responses  toward  an  antigen.  Adjuvant  properties  of  the  polymers  are  mainly 
dependent on their extrinsic and intrinsic properties such as polymer chemistry, 
format, charge and a fine balance between hydrophobicity and hydrophilicity. 
Polymers can also be easily coupled with an antigen/immuno-modulator/ligand 
either  physically  or  chemically.  Efficient  delivery  and  protection  against 
degradation of antigens in vivo are some of the advantages of these polymeric 
adjuvants. Present review focuses on various recent developments in polymeric 
adjuvants and responsible factors that affect their adjuvant properties. 
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INTRODUCTION 
Over the past few decades, focus of materials science is 
shifted  more  towards  soft  materials  research,  especially 
polymers  are  gaining  importance  due  to  their  easy  and 
controllable  synthesis  with  a  number  of  desirable 
modifications  for  various  biological  applications.  Polymers 
are  highly  useful  in  different  biotechnological  as  well  as 
biomedical  applications  such  as  in  the  delivery  of 
drugs/antigens/modified genetic elements, tissue engineering, 
regenerative  medicine and implantation of  medical devices 
(Figure  1).  Polymer  based  drug  delivery  systems  enable 
release of drugs for a longer period of time in a controlled 
way. Specific ligands can easily be coupled with polymers to 
target specific tissues or cells. The appropriate drugs can be 
conjugated with biocompatible polymers to make “polymeric 
pro-drugs” to release such active drugs inside the body (Qian 
et  al.,  2012;  Xiao  et  al.,  2012).  Recently,  researchers  are 
designing  responsive/smart  polymer  based  drug  delivery 
systems  to  release  drugs  in  the  presence  or  absence  of  a 
specific environmental stimuli such as pH, temperature, ionic 
strength etc. (Colson et al., 2012). Uses of these polymers 
have also been reported in the fabrication of biocompatible 
scaffolds for growing several different  mammalian cells to 
regenerate  damaged  organs/tissues.  These  polymeric 
scaffolds can be designed in the form of three dimensional 
porous  networks,  which  will  allow  proper  circulation  of 
nutrients for the optimal growth of the cells. These scaffolds 
are mechanically stable but can easily be degradable (Tripathi 
et al., 2009; Bhat et al., 2011). Polymeric materials have also 
been  used  in  the  fabrication  of  biosensors,  and  in  the 
assessment  of  medical  devices  in  vivo  (Jenke  et  al.,  2012; 
McGraw  et  al.,  2012).  Polymeric  systems  used  for  the 
implantation of medical devices should be biocompatible at 
least  on  their  surface.  Though  many  medical  devices  are 
designed as biocompatible, after implantation, they become 
isolated from devices in the form of fibrous encapsulates that 
are  completely  rejected  by  the  body  (Grodzinski,  1999). 
However,  these  devices  did  not  show  or  induce  any 
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Figure 1. Schematic representation of various polymer applications in the biomedical field. Polymers can be used in tissue 
engineering as scaffolds for growth of mammalian cells, in the activation or suppression of immune responses, carrier for 
delivery of drugs/antigens/modified genetic elements, in biosensors and in coating implantable devices/grafts to minimize 
rejection. 
 
Generally, polymers used for biomedical purposes should 
be biodegradable and are not generating any harmful (toxic) 
effects  within  the  host  as  the  result  of  their  degradation. 
Biodegradable polymers can be natural or synthetic and also 
can be classified as bioerodible or bioresorbable polymers. In 
other  biological  applications,  polymers  can  also  prevent 
biological fouling of surfaces due to non-specific adhesion of 
cells or proteins, which can be toxic for the body (Diagne et 
al., 2012). 
Polymers  are  extensively  used  in  immunology  as  an 
adjuvant,  attenuator,  stimulator  or  suppressor  of  immune 
responses.  As  an  adjuvant,  polymers  are  promising 
candidates  for  enhancing  immune  responses  of  purified 
recombinant  and/or  weak  antigens,  in  the  development  of 
animal disease models without any major bias in the ensuing 
immune  responses,  possibly  by  inducing  all  classes  of 
cytokines  and  in  vaccination  studies  as  carriers.  They  can 
induce specific immune responses, when given along with an 
antigen  (Shakya  et  al.,  2013).  As  an  attenuator,  they  can 
reduce  binding  or  adhesion  of  host  immune  cells  over 
implanted surfaces. Polymers can also be used as an activator 
or suppressor of immune responses (Jalilian, 2012; Kim et 
al., 2012). These points will be discussed in detail below. ISSN: 1314-6246                     Shakya & Nandakumar  J. BioSci. Biotech. 2012, 1(3): 199-210. 
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I. Polymers as immunological attenuators 
Polymers can be used as an agent for reducing immune 
responses  during  transplantation  of  organs  or  tissues  to 
prevent  adverse  immunological  reactions.  Thus,  they  can 
replace  conventional  immunosuppressive  drugs  such  as 
cyclosporin,  which  is  normally  associated  with  risks  of 
infections  and  induction  of  certain  forms  of  cancer.  Blood 
transfusion  studies  revealed  that  covalent  conjugation  of 
monomethoxypolyethylene  glycol  (mPEG),  a  linear  chain 
amphiphilic  molecule,  to  tissues  or  cells  can  significantly 
reduce chances of rejection and can possibly induce tolerance 
(Scott et al., 1997; Scott et al., 1998). Mainly loss of antigen 
recognition and inability of antibodies to bind with epitopes 
are major mechanisms involved in PEGylation. Dampening 
of  T  cell  activity  because  of  increased  resistance  to 
proteolytic degradation after PEGylation was reported with 
egg-white  lysozyme  antigen  (So  et  al.,  1996).  In  addition, 
PEGylation does not impair any cellular signalling pathways 
as  confirmed  by  transplantation  of  PEGylated  isogenic  rat 
pancreatic islets (Chen et al., 2001). Therefore, unlike other 
immuno-suppressive drugs, PEGylation works physically on 
alterating immunogenicity of donor tissue without disturbing 
recipient’s  immune  responses.  Apart  from  PEGylation, 
coating  of  polyelectrolytes  on  the  cell  surface  can  also 
attenuate  host  immune  responses.  Recently  a  versatile 
approach has emerged based on layer-by-layer self-assembly 
of polyelectrolytes over red blood cells with an aim to make 
universally  acceptable  RBCs  (Mansouri  et  al.,  2011). 
Polyelectrolytes  can  attenuate  or  suppress  binding  of 
antibodies to the donor red blood cells. These polyelectrolyte 
coatings  were  composed  of  four  bilayers  of  alginate  and 
modified chitosan with phosphorylcholine, which was further 
surrounded by another two layers of alginate and modified 
polyethylene  glycol.  While  encapsulating  with 
polyelectrolytes, RBCs retained viability and functionality as 
confirmed  by  haemolysis  assay.  The  immunologic 
attenuation was confirmed by reduction in the recognition of 
antigens on RBC surface by respective antibodies.  
Recently,  biological  therapy  (including  monoclonal 
antibodies to cytokines to specifically inhibit their functions, 
receptor blocking antibodies and new fusion receptors) has 
emerged  as  a  promising  approach  to  treat  allergic  and 
autoinflammatory diseases (Broderick et al., 2011). One of 
the major disadvantages of using these bioactive proteins is 
their  immunogenicity.  One  approach  is  to  humanize  these 
therapeutic  proteins  for  better  tolerance  (Almagro  et  al., 
2008).  PEGylation  is  another  well-known  strategy  for 
improvement  of  pharmacokinetic,  pharmacodynamic  and 
immunological  properties  of  therapeutic  proteins/peptides. 
Polyethylene glycol (PEG) is a typical polymer, which has 
been used for conjugation of therapeutic proteins. Generally, 
PEG  conjugation  improves  circulating  half-life,  reduces 
toxicity  and  minimizes  immunogenicity  of  therapeutic 
proteins.  In  1977,  for  the  first  time,  Auchowski  et  al., 
demonstrated that conjugation of PEG to protein reduced the 
immunogenicity  and  antigenicity  of  protein  with  minimum 
loss of functional activity (Abuchowski et al., 1977). Later, 
the molecular weight ratio of mPEG to protein was shown to 
determine immunotolerogenicity of mPEG proteins (So et al., 
1999).  In  pharmaceutical  research,  various  PEG  coupled 
therapeutics like l-asparaginase, growth hormone, cytokines 
are widely approved for human use (Abuchowski et al., 1984; 
Jevsevar  et  al.,  2010).  However,  few  studies  have  also 
reported significant loss of activity of protein by PEGylation 
(Bowen et al., 1999). Moreover, because of the difficulties 
involved  with  the  PEGylation  reactions,  separation  and, 
characterization of the structure and activity of the products, 
new bio-processing conditions are being developed for wider 
application of PEGylated conjugates in medicine (Gonzalez-
Valdez et al., 2012). Furthermore, site-selective PEGylation 
is used currently  to obtain a single isomer  with increasing 
degree of homogeneity and bioactivity by targeting protein 
N-terminus  and  free  cysteines  but  further  amino  acid 
positions can also be PEGylated by using disulphide bridges, 
glutamines  and  C-terminus  and,  sites  of  O-  and  N-
glycosylation or the glycans of a glycoprotein (Pasut et al., 
2011).  
Several  labs  are  also  designing  stimuli-responsive 
polymers for conjugation of therapeutic proteins, which can 
be used for treating tumours and inflammation. The  major 
advantage with these polymers is the ease with which their 
functional activities can be switched on/off in the presence or 
absence of  a specific stimulus such as pH, temperature and 
ionic strength (Chilkoti et al., 2002). Similar to PEGylation, 
conjugation  of  proteins  with  polyvinyl  alcohol  (PVA)  was 
also  shown  to  cause  loss  of  most  of  the  antigenicity  of 
antigens (Atassi et al., 1991). 
II. Polymers as immuno-suppressors 
Suppression of immune system can either be desirable or 
dangerous  for  the  body  during  organ  transplantation. 
Supression of the host immune system against infections is 
highly undesirable but increasing the chances of therapy for ISSN: 1314-6246                     Shakya & Nandakumar  J. BioSci. Biotech. 2012, 1(3): 199-210. 
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allergies and autoimmune diseases by dampening an ongoing 
immune response is favourable. Generally, state of immuno-
suppression  achieved  by  immuno suppressive  drugs  are 
associated  with  undesirable  consequences  of  toxicities 
(Descotes, 2004). These consequences may be circumvented 
by the use of polymeric nanoparticles. Recently, few studies 
were  reported  the  immuno-suppressive  role  of  polymeric 
nanoparticles directly, such as inhalation of canban nanotubes 
(CNTs),  which suppressed the B cell responses and TGF -α 
was suggested as a key element in the suppression process 
(Mitchell et al., 2009). Another example is the water soluble 
polyhydroxy C60 (fullerene) that has shown inhibitory effect 
on  type  1  hypersensitive  reaction  (Ryan  et  al.,  2007). 
Similarly, other polymers such as chitosan, poly(lactide-co-
glycolide)  (PLGA),  polymethyvinylether-co-maleic 
anhydride  based  nanoparticles  and  dendrosomes  have  also 
been used in the suppression of type I and III hypersensitive 
reactions  (Balenga  et  al.,  2006;  Gomez  et  al.,  2008). 
Recently, a synthetic peptide based dendrimers have shown 
inhibitory effect on experimental allergic encephalomyelitis, 
model for multiple sclerosis (MS) (Wegmann et al., 2008). 
On  the  otherhand,  natural  polymers  like  water  soluble 
polysaccharides  from  the  alga,  Sargassum  fusiforme, 
composed of d-fucose, l-xylose, d-mannose and d-galactose 
was  shown  to  protect  against  cyclophosphamide  induced 
immunosuppression  with  a  possibility  of  reducing  the 
severity  of  chemotherapeutic  immunosuppression  (Chen  et 
al., 2012). 
Polymeric nanoparticles as carriers of immunosuppressors 
On  the  otherhand,  there  are  few  studies  reporting  the 
effect  of  polymeric  nanoparticles  as  carriers  in  treating 
autoimmune diseases. For example, PLGA particles loaded 
with  an  autoantigen  collagen  type  II,  which  is  present 
abundantly  on  the  articular  cartilage,  site  of  inflammatory 
attack in arthritis, suppressed arthritis significantly (Kim et 
al.,  2002).  Similarly,  suppression  of  diabetes  in  a  mouse 
model  was  observed  with  the  delivery  of  IL-10  cytokine 
expressing DNA using polymeric nanoparticles (Basarkar et 
al.,  2009).  It  was  also  possible  to  treat  experimental 
autoimmune  uveoretinitis  with  betamethasone  loaded 
polylactide particles (Sakai et al., 2006). Furthermore, silica 
nanoparticles loaded with cytotoxic T cell associated antigen 
was  used  for  the  treatment  of  thyroiditis  in  canine  model 
(Choi et al., 2008). Mechanisms of action of these particles in 
vivo are yet to be deciphered. However, these nanaoparticles 
are not only biocompatible and biodegradable but also can 
deliver  therapeutic  proteins  efficiently  (Yun  et  al.,  2012). 
Recently,  polymeric  miscelles  made  up  of  methoxy 
poly(ethylene  oxide)-b-poly(ε-caprolactone)  as  vehicles  for 
the solubilization and delivery of cyclosporine A (Hamdy et 
al., 2011) and rapamycin loaded pH-sensitive, biocompatible 
acetylated  dextran  (Ac-DEX)  microparticles  were  used 
(Kauffman et al., 2011) for immunosuppression applications. 
III. Polymers as immunological adjuvants 
An  adjuvant  is  not  only  an  important  component  in 
animal  model(s)  development,  which  are  essential  tools  to 
delineate  pathogenesis  of  human  diseases,  but  also  in 
potential  vaccine  formulations  to  prevent/contain  such 
diseases.  Usually,  adjuvants  along  with  an  antigen  can  be 
taken by antigen presenting cells (APCs) and the processed 
antigen can be presented on its cell surface to activate T cells. 
Apart  from  cell-cell  contact  and  co-stimulatory  signals, 
stimulation via secreted proteins like cytokines may also be 
required for the optimal activation of T cells, which in turn 
could potentially activate other T and B cells in the vicinity 
into memory as well as effector cell populations. Activated B 
cells  can  further  differentiate  into  short  and  long-lived 
memory B cells and plasma B cells, which produce sustained 
antibodies against the antigen (Shlomchik et al., 2012; Winter 
et al., 2012).  
There are only few adjuvants that are approved for human 
use by US Food and Drug Administration (FDA) including 
alum,  MF59,  virosomes  and  montanide  ISA  51.  Among 
them,  alum  is  a  well-studied  material  and  is  known  for 
tremendous  activation  of  antibody  responses  but  with  less 
cellular activation (HogenEsch, 2002). Alum can induce good 
immune  responses,  but  safety  concerns  are  still  associated 
with  these  salts  (Tomljenovic  et  al.,  2012).  Although 
emulsions have the capacity to encapsulate various antigens 
to induce antibody and cell mediated immune responses, they 
are unable to induce Th1-type immune responses. Therefore, 
there is a potential need for immunologically inert adjuvants. 
In  this  context,  polymers  have  the  potential  to  be  used  as 
alternatives  because  of  their  effectiveness  and  safety. 
Polymers are known to enhance the shelf-life of antigens and 
are capable of inducing long lasting antibody responses as 
well as cell-mediated immunity (Shakya et al., 2011a). The 
immunomodulators  or  ligands  targeting  specific  cells  can 
easily be coupled to polymers, which can easily be developed 
in the form of micro/nano based particulate adjuvants such as 
emulsions,  microparticles,  liposomes  (Huang  et  al.,  2009; 
Chen CH et al., 2012). Normally these particulate systems are ISSN: 1314-6246                     Shakya & Nandakumar  J. BioSci. Biotech. 2012, 1(3): 199-210. 
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directly taken up by APCs and present the associated antigens 
on their cell surface to T cells.   
Beside  these  formulations,  researchers  focus  is  now 
shifting  towards  nanoparticles  based  on  polymethacrylates, 
poly(lactide-co-glycolide)  PLGA,  polycaprolactones  (PCL), 
polyvinylpyrrolidone (PVP) etc. (Madan et al., 1997; Benoit 
et  al.,  1998;  Lou  et  al.,  2009;  Moon  et  al.,  2012).  Unlike 
conventional  adjuvants,  these  polymeric  particles  are 
biocompatible,  degradable  and  are  capable  of  delivering 
antigens more efficiently. They can release antigen in vivo in 
a  controlled  manner  apart  from  stabilizing  these  antigens, 
which is a major concern in vaccine formulations due to the 
liable  nature  of  many  protein  antigens.  For  example, 
amphiphilic  polymer  composed  of  1,6-bis(p-
carboxyphenoxy)  hexane  and  1,  8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane  has  shown  to  stabilize  Bacillus  anthracis 
antigen in the form of nanoparticles. These nanoparticles can 
also  be  stored  for  a  longer  time,  thus  decreasing  costs  of 
vaccination considerably (Petersen et al., 2012).  
For  other  applications,  oil  based  adjuvants  are  more 
popular, for example in the induction of autoimmunity for the 
development  of  new  disease  models  to  study  pathological 
mechanisms  in  human  diseases.  Apart  from  oil  and  alum 
based compounds, various carbohydrates (acylated dextran, 
mannan,  lipomannan,  inulin  isoforms,  lentinnan,  chitosan) 
are also capable of activating the immune system (Petrovsky 
et al., 2011). Despite their good adjuvant potential, they still 
possess  considerable  level  of  toxicity  and  degradation 
problems. Recently our group discovered a novel application 
for  the  thermo-responsive  polymer,  poly-N-
isopropylacrylamide (PNiPAAm), which acts as an adjuvant 
for  enhancing  the  immunogenicity  of  the  self-antigen, 
collagen type II (CII) to induce a variant of collagen induced 
arthritis  (CIA),  a  classical  animal  model  of  Rheumatoid 
arthritis. CIA is used to study disease pathogenesis of RA and 
to  discover  appropriate  targets  for  its  therapy.  Mice 
immunized  with  polymer-CII  developed  arthritis  with  a 
concomitant  development  of  an  anti-CII  antibody  response 
comprising  of  all  the  IgG  subclasses.  After  mixing  with 
polymer,  CII  still  retained  its  native  epitopes  and  native 
confirmation of CII is a pre-requsite for its arthritogenicity 
(Schulte  et  al.,  1998).  Usually,  adjuvants  enhance 
immunogenicity by acting as a depot for slow release of an 
antigen for sustained period of time, as an immunomodulator 
or help in the processing of an antigen in a better way by 
antigen  presenting  cells.  In  our  experiments,  gelated 
PNiPAAm acted as a reservoir for CII and released CII at 
physiological concentrations and also acted as a modulator of 
immune system at the cellular level. A physical interaction of 
CII with polymer was better compared to covalent linkage for 
the  induction  of  an  antibody  response.  Inside  the  host, 
polymer precipitates around the CII (gelation) and entrapped 
it. Moreover, high molecular weight of polymer was better 
for  inducing  robust  immune  responses  due  to  its  strong 
precipitation  property  compared  to  small  chains  of  the 
polymer  (Shakya  et  al.,  2011a).  Unlike  the  conventional 
adjuvants,  immune  response  induced  by  PNiPAAm  is 
independent of TLRs. In addition, polymer as an adjuvant is 
immunologically inert and at the same time did not alter the 
genetic susceptibility of CII. Activation of serum cytokines 
IFN-,  IL-4  and  IL-17  were  observed  few  days  after  the 
immunization  of  mice  with  polymer-CII  (Shakya  et  al., 
2011b). 
Polymers  have  also  been  reported  as  a  promising 
candidate for their use as a scaffold for growing chondrocytes 
in  the  regeneration  process  of  articular  cartilage  within 
arthritic joints. Natural biopolymers such as collagen based 
polymers  are  known  as  good  polymers  for  supporting  the 
growth of primary chondrocytes (Li et al., 2005). Apart from 
these  natural  polymers,  various  synthetic  polymer(s)  based 
scaffolds have also been tried for cartilage regeneration. For 
example, neocartilage formation was observed using poly-N-
isopropylacrylamide-co-acrylic  acid  (PNiPAAm-co-AAc) 
polymer seeded with rabbit chondrocytes in the presence of 
transforming growth factor-β3 (TGF-β3) (Yun et al., 2008). 
In  another  study,  acrylate  based  polymethacrylate-gelatin 
cryogel scaffold has shown promising scaffold property for 
primary  chondrocytes  during  cartilage  tissue  engineering 
(Singh et al., 2010). Recently, a more improved microtubular 
oriented PLGA scaffold was developed for in vitro cartilage 
regeneration (Zhang et al., 2012). 
IV. Factors affecting the immunogenicity of an 
antigen with polymeric adjuvants 
Although  polymers  are  considered  as  promising 
candidates  for  induction  of  immune  responses,  there  are 
several factors which could affect adjuvant potential of them 
such  as  size,  shape,  format,  polymer  chemistry  and  a  fine 
balance  of  hydrophobicity  and  hydrophilicity  (Figure  2). 
These factors are playing an important role in determining 
their  adjuvant  property,  which  will  be  discussed  in  detail 
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Figure 2. Schematic representation of different polymer formats and the activation of the immune system. Polymers can exist 
in solution, gel and particulate formats and antigen can be easily encapsulated within them. Antigen released from these 
polymers is taken up by antigen presenting cells, processed and presented in the form of peptides to T cells leading to their 
activation, secretion of different cytokines, an effective T-B co-operation, antibody production and the effector functions. 
 
1. Polymer formats versus adjuvant potential 
Particulate size of the polymers is an important factor for 
their  internalization  by  APCs  and  the  efficacy  of  an 
encapsulated  antigen.  These  particulates  can  be  taken  into 
lymphoid  organs  either  within  interstitial  space  or  by 
peripheral  dendritic  cells  (DCs)  (Swartz  et  al.,  2008).  The 
particles with more than 100 nm are directly internalized by 
peripheral DCs and taken into lymph nodes. While particles 
with less than 50 nm diameters are directly transported into 
lymphatic vessels within interstitial space and internalized by 
resident immature DCs (Reddy et al., 2006a; Reddy et al., 
2006b).  Moreover, particle size is also of importance during 
antigen delivery across the mucosal surfaces in mucous based 
vaccines. Generally, mucus layer restricts entry of particles of 
the size more than 100 nm, while particles with 50 nm size ISSN: 1314-6246                     Shakya & Nandakumar  J. BioSci. Biotech. 2012, 1(3): 199-210. 
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can  easily  penetrate  through  this  barrier (Cone,  2009). 
Because of this, it is a challenge to deliver vaccines through 
mucosal  route.  Particles  in  micro/nano  range  can  also 
determine other immunological properties like antigen uptake 
by APCs and their maturation (Kim et al., 2010). Normally, 
higher  cell  uptake  is  observed  with  nano -sized  particles 
compared  to  micro -sized  particles  (Yue  et  al.,  2010) . 
Nanoparticles in vaccine research are promising vehicles for 
better antigen delivery due to tunable chemical and physical 
properties, biocompatibility, stability, high loading capacity, 
specificity  to  target  cells,  and  other  immuno -modulator 
properties. They can also be made responsive for the target 
cell  environment  by   using  smart/intelligent  or  stimuli -
responsive  polymer  based  particulates (Cui  et  al.,  2012). 
Nanoparticles  could  overcome  the  natural  barriers  such  as 
reticuloendothelial system and can easily be cleared though 
kidney  glomeruli.  Non-specific  accumulation  can  also  be 
minimized  by  modulation  of  physio-chemical  properties  of 
the  nanoparticles.  Particles  in  mic ro/nano  size  can  be 
synthesized by various approaches like physical assembly of 
interactive polymer chains, polymerization of monomers and 
cross-linking  of  pre-formed  polymers.  Mostly,  chitosan, 
poly-L-lysine,  dextran,  alginic  acid,  hyalauronic  acid,  and 
heparin  natural  polymers  can  be  fabricated  in  the  form  of 
nanoparticles.  In  the  synthetic  class,  polymethacr ylates, 
polyglycolides,  poly(d,  l-lactic-co-glycolic  acid),  poly(-
caprolactanes) based particulate systems have been designed 
for different vaccines (Benoit et al., 1998; Lou et al., 2009; 
Moon et al., 2012).  
The  particulate  system  can  be  designed  in  a  way  to 
stimulate or suppress an immune response based on the need 
of the application. Kreuter and his group in 1986 analyzed the 
size  effect  of  the  polymethylmethacrylate  and  polystyrene 
particles encapsulated  with influenza  vaccines,  which  were 
synthesized  through  gamma  radiation.  Due  to  less 
aggregation  of  these  polymers,  they  have  synthesized 
different size-based particles in the range of 62-306 nm and 
found  a  better  adjuvant  effect  with  smaller  particles 
compared to bigger particles (Kreuter et al., 1986). Moreover, 
an advantage with smaller sized particles is the availability of 
high surface area for adsorption of the antigens. This allows 
high encapsulation of antigens on the particles. Stimulation 
of  macrophages  and  other  immuno-competent  cells  are 
probable mode of action of  these particles-based adjuvants 
(Gaspar  et  al.,  1992).  Other  than  the  particulate  format, 
polymers are also being used in solution form as adjuvants. 
Recently, our  group demonstrated the adjuvant capacity of 
synthetic  stimuli-sensitive  polymer  based  poly-N-
isopropylacrylamide as an adjuvant in solution form. Poly-N-
isopropylacrylamide  based  polymers  are  temperature-
sensitive and show reversible phase transition at their cloud 
point around ~32°C. These polymers in solution form can be 
mixed with any antigen, in our case with an autoantigen CII, 
and can be injected easily. This polymer precipitated over the 
antigen  inside the  host. The  exact  mechanism of action of 
these polymers is yet to be completely delineated. However, 
slow release of the antigen during long period of time could 
possibly be considered as the mechanism of action. With an 
antigen, these polymers can stay in the lymphatic system for 
more than one  month.  As an adjuvant, these polymers are 
biocompatible and do not show any type of toxicities both in 
vitro  and  in  vivo.  Polymer-CII  mixture  can  induce  both 
antibody and cell mediated immune responses significantly 
(Shakya et al., 2011a). Interestingly, unlike the conventional 
adjuvants  like  CFA  and  IFA,  polymer  based  adjuvants 
induced all the types of effector T cells, thereby effectively 
precluding any major bias in the ensuing immune responses. 
Simialarly,  we  observed  adjuvant  property  of  poly-N-
isopropylacrylamide  is  TLR  independent  unlike  TLR2 
dependent conventional complete Freund adjuvant (Shakya et 
al., 2011b). 
2. Polymer chemistry 
Polymer  chemistry  is  another  important  factor  for  the 
adjuvant capacity of polymers. Earlier Bennett et al., (Hunter 
et al., 1984)  studied adjuvant potential of non-ionic block 
copolymers based on the variation of copolymer composition. 
They have tested 17 surface active agents that can enhance 
humoral immune responses and inflammation. These agents 
were composed of hydrophobic polyoxypropylene (POP) and 
hydrophilic  polyoxyethylene  (POE)  blocks,  which  are 
different from each other in terms of molecular weight and 
types  of  linking  between  the  blocks.  These  agents  were 
emulsified  in  oil-in-water  and  loaded  with  bovine  serum 
albumin as an antigen. Large and insoluble copolymers with 
POE  blocks  flanking  with  POP  chains  were  effective  for 
antibody  formation.  Moreover,  activation  of  complement 
system  with  the  production  of  chemotactic  factors  were 
observed with these block copolymers. Adjuvant activity and 
inflammation decreased substantially with as increasing POE 
content  in  the  block  copolymers.  In  another  preparation, 
block  copolymers  with  POP  blocks  flanking  with  POE 
induced granuloma formation rather than antibody formation. 
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proportions of POE and POP content induced low  immune 
response  with  an  increase d  inflammation  (Hunter  et  al., 
1984). Moreover, in a comparison study, effect of polymer 
composition on immunological properties of uricase antigen 
was  studied  in  conjugation  with  different  polymers; 
polyvinylpyrrolidone  (PVP),  poly( N-acryloylmorpholine), 
branched  monomethoxy  polyethyleneglycol  and  linear 
monomethoxypolyethyleneglycol.  Antigenicity  and 
immunogenicity of uricase was altered and dependent on the 
type of polymer used. Out of these four conjugates, PVP has 
shown  to  have  highest  adjuvant  property  while 
monomethoxypolyethylene glycol reduced the antigenicity of 
uricase significantly (Caliceti et al., 1999). Recently, we have 
tested  the  temperature  responsive  copolymers  poly-N-
isopropylacrylamide-co-allylamine  (PNiPAAm-co-AAm)  as 
an adjuvant with CII autoantigen in mice. PNiPAAm based 
copolymers  were  synthesized  through  copolymerization  of 
different  proportions  of  allylamine  (AAm).  We  observed 
reduced antibody formation with an increasing AAm content 
in  the  PNiPAAm-co-AAm  terpolymer.  In  this  case, 
copolymerization  of  AAm  decreased  the  cloud  point  of 
PNiPAAm  and  as  a  result  of  this  inherent  precipitation 
property  immune  responses  were  affected  significantly 
(Shakya et al., 2011a). 
3. Molecular weight 
Molecular  weight  significantly  affects  the  adjuvant 
potential of a polymeric adjuvant. Higher molecular weight 
polymers  enhanced  the  immune  responses  significantly 
compared  to  low  molecular  weight  polymers.  Besides 
molecular weight, the distribution of polymeric chains is also 
another important factor that can affect adjuvant potency of a 
polymer. For the first time Hunter et al., in 1991 has observed 
the  effect  of  molecular  weight  of  the  copolymer  using 
polyoxypropylene  (POP)  and  polyoxyethylene  (POE) 
adjuvant system. Mean antibody titre values were effectively 
increased  as  the  molecular  weight  of  POP  blocks  of 
copolymer  increased  in  POP-b-POE  (Hunter  et  al.,  1991). 
Similarly,  we  have  also  observed  the  effect  of  increasing 
molecular weight of PNiPAAm on its adjuvant effect. 120 
kDa  average  molecular  weight  of  PNiPAAm  induced  a 
higher  antibody  response  when  injected  along  with  CII 
compared to PNiPAAm with 70 kilodaltons (Shakya et al., 
2011a). 
4. Hydrophilic and hydrophobic balance 
Hydrophilic  and  hydrophobic  effect  of  polymers  is 
playing an important role in determining their adjuvant effect. 
Hydrophobic domain of polymers is favourable for protein 
adsorption, which recruits more primary antigen presenting 
cells for phagocytosis of the antigen, thus affecting potential 
retention of antigens with the polymers (Nguyen et al., 2009). 
For the first time, the effect of particle(s) hydrophobicity on 
its  adjuvant  properties  was  demonstrated  with  oral 
immunization  (Eldridge  et  al.  1990),  where  higher 
hydrophobicity  favoured  a  significantly  higher  immune 
response (Eldridge et al., 1991). This observation was further 
supported  by  the  study  of  Youan  et  al.,  who  synthesized 
hydrophobic  polycaprolactone  (PCL)  particles,  which 
enhanced the phagocytosis of PCL particles by macrophages 
(Youan  et  al.,  1999).  Cellular  mechanisms  by  which 
hydrophobic  property  affects  adjuvant  activity  are  not  yet 
clear.  However,  how  they  affect  the  humoral  immune 
responses  through  involvement  of  TLRs  and  induced 
maturation of dendritic cells are well documented (Ferreira et 
al., 2012). Apart from hydrophobicity, hydrophilic moieties 
of polymers are also important to determine their adjuvant 
potential.  Generally,  hydrophilic  moiety  of  an  adjuvant 
mixture  prevents  non-specific  interactions  of  proteins  with 
cells. Physically, hydrophilic part helps in the solubility of 
antigens  with  an  adjuvant,  which  helps  in  homogenous 
distribution of antigen  within the polymer-antigen  mixture. 
For  example,  PLGA  nanoparticles  coated  with  PEG 
molecules help in non-specific interaction of particles with 
other  cells.  On  other  hand,  other  property  like  loading 
efficiency  of  antigens  was  substantially  decreased  after 
coating  with  PEG  molecules.  Hydrophilic  domain  of  an 
adjuvant is also important in the aggregation of nanoparticles 
(NPs) on mucus and their transport across the mucus layer. 
Generally, short and dense grafting of PEG molecular chains 
stabilized  the  NPs  compared  to  longer  and  well  dispersed 
grafted  PEG.  Larger  PEG  chain  might  get  entangled  with 
each  other  and  prevent  NPs  phagocytosis  by  APCs. 
Therefore, optimum hydrophilic effect is an important factor 
for a better adjuvant effect (Huang et al., 2000; Lai et al., 
2009).  Recently,  contradictory  findings  were  reported  with 
the adjuvant properties of saponins obtained from Chiococca 
alba,  a  flowering  plant  in  the  coffee  family,  Rubiaceae. 
Usually  saponins  are  tripene  bidesmosides,  which  contain 
glycidic moieties. The adjuvant activity of saponins increased 
with  the  increasing  length  and  hydrophilicity  of  the  sugar 
chain attached to C-28 (Nico et al., 2012).  
Recently, we found that a fine balance of hydrophilic and 
hydrophobic  moieties  determined  the  adjuvant  effect  of 
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immune  responses  with  the  CII  antigen.  We  screened  four 
different  synthetic  polymers  having  hydrophilic  and/or 
hydrophobic moiety, viz., poly(N-allylisopropylamine), poly-
N-isopropylacrylamide,  poly-N-isopropylacrylamide, 
polybut-3-en-2-one.  In  both  mice  and  rats,  poly-N-
isopropylacrylamide showed highest adjuvant activity among 
all  the  polymers.  Structurally  this  polymer  have  isopropyl 
group attached to an amide group, which is contributing more 
to its hydrophobic nature. Interestingly, adjuvant activity was 
decreased in polyacrylamide followed by polybut3-en-2-one, 
which has ketone group contributing to the hydrophobicity of 
this  polymer.  Furthermore,  poly(N-allylisopropylamine)  did 
not  show  any  adjuvant  effect  because  of  its  complete 
hydrophilic nature due to the presence of amine groups. Thus, 
a  fine  balance  of  hydrophilicity  and  hydrophobicity  is 
important  for  determining  the  adjuvant  activity  of  a 
polymeric adjuvant. 
5. Charge 
Charge of the polymers is another factor for deciding their 
adjuvant efficacy. Charge can affect the loading efficiency, 
stability,  bio-adhesive  properties  of  antigens,  especially  in 
DNA  vaccines  (Sharma  et  al.,  2009).  Generally,  cationic 
nano-gels  can  easily  form  complexes  with  DNA  by 
electrostatic interactions,  thereby  increasing the stability of 
an  antigen.  Positive  charge  can  also  facilitates  higher 
transfection  efficiency  by  favouring  interactions  of  the 
polymer  with  the  negatively  charged  proteins  of  cell 
membrane (Mao et al., 2001). Moreover, cationic polymer(s) 
mediated  delivery  systems  enhanced  both  localized  and 
systemic  immunogenicity  compared  to  other  polymers 
(Kumar et al., 2002).  
A series of polyethylamines (PEI) complexed with DNA 
and  their  in  vivo  expression  was  checked  in  a  study  to 
enhance adaptive  immune responses.  All PEI  were able to 
increase 20 to 400 fold DNA expression in vivo and 10 to 25 
fold more CD8
+ T cell responses in BALB/c and C57BL/6J 
mice  respectively  (Grant  et  al.,  2012).  Moreover,  PEI 
complexed DNA improved antigen-specific Th1 type of cells 
and  humoral  mediated  immunity  substantially.  Apart  from 
their adjuvant properties, PEI also has the ability to protect 
DNA from degradation.  Another cationic lipopolymer based 
on liposome-polyethylene glycol-polyethyleneimine complex 
(LPPC)  proved  to  be  a  promising  adjuvant,  which  can 
strongly adsorb the antigen on its surface leading to enhanced 
immune responses. LPPC has enhanced the antigen uptake 
and  surface  marker  expression  on  immune  cells  with  an 
increased activation of Th1-type of immunity (Chen et al., 
2012). 
CONCLUSIONS  
Polymers are having many promising applications in the 
formulation of new generation vaccines, implantation studies, 
therapeutics, development of new disease models and in the 
activation  or  suppression  of  immune  responses.  As  an 
adjuvant,  polymers  can  be  efficiently  used  to  deliver  an 
antigen  and  fine  tune  the  ensuing  immune  responses. 
Adjuvant properties of polymers are mainly dependent on its 
extrinsic and intrinsic properties such as polymer chemistry, 
format, molecular weight, charge and a fine balance between 
hydrophobicity and hydrophilicity. Polymers are proved to be 
promising candidates for antigen delivery and when mixed 
with  an  antigen  can  induce  an  antigen-specific  immune 
response. But several questions remain to be explored further 
like mechanisms of antigen processing and presentation, type 
of  cells  recruited  at  the  injection  site  and  the  nature  of 
signaling pathways involved during the induction of immune 
responses involving polymeric adjuvants. 
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